Science AI Journal
Medicine · Research topic

Open research questions in Cholinesterase and Neurodegenerative Diseases

178 gap statements mined from Cholinesterase and Neurodegenerative Diseases papers in our 7.9M-paper local library, which holds 777 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Cholinesterase and Neurodegenerative Diseases? See the ranked Medicine journals.

What the literature leaves open

  • Lack of methods to simultaneously determine AChE content and catalytic activity. Traditional methods have limitations in terms of detection time, dynamic range, and detection limits.

    Dual Monitoring of Blood Acetylcholinesterase Content and Catalytic Activity Utilizing Fluorometry-Integrated Surface Plasmon Resonance · 2025 · DOI

  • There is a lack of complete cure for Alzheimer's disease. I3C and DIM have not been previously studied for their anti-AD effects. The mechanisms of I3C and DIM in mitigating β-amyloid-induced neurotoxicity are not well understood.

    Indole-3 Carbinol and Diindolylmethane Mitigated β-Amyloid-Induced Neurotoxicity and Acetylcholinesterase Enzyme Activity: In Silico, In Vitro, and Network Pharmacology Study · 2024 · DOI

  • One challenge is the complexity of Alzheimer's disease, which makes it difficult to develop effective treatments. Another challenge is the lack of understanding of the disease's aetiology and pathophysiology. The paper also highlights the challenge of managing neuropsychiatric symptoms, such as anxiety and depression, which are common in Alzheimer's disease patients.

    Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease · 2024 · DOI

  • Further research is warranted to optimize and combine the structures of these lead fragments and those of additional compounds, and to evaluate their in vitro and in vivo efficacy, with the ultimate goal of developing improved therapeutic strategies for Alzheimer’s disease and other cholinergic disorders.

    Quantum–Chemical Multiligand Simultaneous Docking of Three-Membered Rings in the Active Site of Butyrylcholinesterase · 2026 · DOI

  • Future research should focus on designing multitarget chalcone hybrids capable of simultaneously modulating cholinesterases, MAO-B, oxidative stress, inflammation, and amyloid pathways.

    Substituted Chalcones as Neuroprotective Agents: A Review · 2026 · DOI

  • There is a need for more effective and selective inhibitors of acetylcholinesterase and butyrylcholinesterase. Prior work has focused on developing inhibitors for these enzymes, but there is still a gap in understanding the mechanism of action of these inhibitors.

    Bis -Schiff base derivatives of S -flurbiprofen as potent dual cholinesterase inhibitors: synthesis, in vitro biological evaluation and computational insights · 2026 · DOI

  • There is a need for new therapeutic agents for metabolic and neurodegenerative diseases. The effects of D. viscosa on protein glycation and neurotoxic enzyme activity are not well studied.

    Oxidative stress mitigation by leaves of Dodonaea viscosa Jacq. flavonoid-rich extract confers protection against protein glycation, amyloid formation, and neurotoxic enzyme activity · 2026 · DOI

  • Future studies should investigate the experimental validation of the findings. Future research should explore the development of new lead compounds for AD treatment. Further studies should consider the potential of thiazole–semicarbazide hybrids as dual inhibitors for AD treatment.

    In silico investigation of thiazole–semicarbazide hybrids as dual GSK-3β/Tau inhibitors for Alzheimer’s disease · 2026 · DOI

  • The lack of efficacy in reversing okadaic acid-induced toxicity highlights the need for further structural optimization to broaden the neuroprotective spectrum. The study only evaluated the neuroprotective effects of four representative N-benzyl-2-[4-(aryl)-1H-1,2,3-triazol-1-yl]ethan-1-imine oxides.

    Neuroprotective Evaluation of N-Benzyl-2-[4-(Aryl)-1H-1,2, 3-Triazol-1-Yl]ethan-1-Imine Oxides · 2026 · DOI

  • The gap in current research is the lack of effective treatments for neurodegenerative diseases. The study highlights the need for further structural optimization to broaden the neuroprotective spectrum.

    Neuroprotective Evaluation of N-Benzyl-2-[4-(Aryl)-1H-1,2, 3-Triazol-1-Yl]ethan-1-Imine Oxides · 2026 · DOI

  • The precise mechanism of action of pterostilbene in the context of neurodegenerative diseases remains not fully understood. The study must integrate multiple techniques, including network pharmacology and molecular docking analysis, to analyze the multitarget mechanisms of pterostilbene.

    Integrative Network Pharmacology and Molecular Docking Analysis Reveals the Multitarget Mechanisms of Pterostilbene in Neurodegenerative Diseases · 2026 · DOI

  • Further optimization of the coumarin carboxamides is needed to improve their pharmacokinetic profiles. Investigation of the compounds' effects on other cancer cell lines is necessary. Evaluation of the compounds' potential as therapeutic agents in animal models is required.

    Design, synthesis, biological evaluation, and in silico analysis of novel coumarin carboxamides as acetylcholinesterase and butyrylcholinesterase inhibitors and anticancer agents · 2026 · DOI

  • The study is based on in silico analysis and warrants further experimental validation. The compounds demonstrated limited BBB permeability, potentially affecting their ability to target central nervous system diseases.

    Exploring the Therapeutic Potential of Cannabis Constituents in Parkinson's Disease: Insights from Molecular Docking Simulations · 2026 · DOI

  • Current treatments for Parkinson's disease do not target neuronal degeneration. There is a need for novel compounds that can target Parkinson's disease biomarkers.

    STRUCTURE-BASED DRUG DESIGN FOR PARKINSON'S DISEASE: MOLECULAR DOCKING ANALYSIS OF NOVEL COMPOUNDS · 2026 · DOI

  • The need to balance therapeutic efficacy and safety in drug design. The challenge of predicting toxicity and synthetic accessibility of novel compounds.

    Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases · 2026 · DOI

  • The lack of multifunctional drugs that can target multiple factors involved in Alzheimer and Parkinson diseases. The need for drugs with enhanced therapeutic efficacy and safety. The limitation of existing drugs such as hepatotoxicity.

    Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases · 2026 · DOI

  • The true exposure and survival rates are likely underestimated due to underreporting and limited statistical data, - The study only used C2C12 myoblasts and did not investigate other cell types, - The study did not investigate the long-term effects of Pz-1…

    Inhibition of Muscle-Specific Protein Kinase (MuSK) Releases Organophosphate-Aged Acetylcholinesterase (AChE) from C2C12 Cells · 2025 · DOI

  • Investigate the long-term effects of Pz-1 treatment, - Examine the efficacy of Pz-1 in other cell types and in vivo models, - Explore the potential of Pz-1 as a therapeutic agent for OP exposure, - Investigate other small molecules that may inhibit MuSK and rescue AChE…

    Inhibition of Muscle-Specific Protein Kinase (MuSK) Releases Organophosphate-Aged Acetylcholinesterase (AChE) from C2C12 Cells · 2025 · DOI

  • The majority of research is limited to in vitro experiments or molecular docking studies, - A scarcity of in vivo or clinical confirmations raises concerns about bioavailability, - The ability to cross the blood-brain barrier, metabolic stability, and safety profiles are not well…

    Marine-Derived Natural Substances with Anticholinesterase Activity · 2025 · DOI

  • Further interdisciplinary research is essential to enhance the therapeutic potential of marine-derived compounds, - In vivo or clinical confirmations are needed to validate the efficacy of marine-derived compounds, - Investigation into the bioavailability, ability to cross the blood-brain barrier, metabolic stability, and safety profiles of marine-derived…

    Marine-Derived Natural Substances with Anticholinesterase Activity · 2025 · DOI

  • Finding novel molecules for the cure of AD, - Investigating the effects of I3C and DIM on other neurological…

    Indole-3 Carbinol and Diindolylmethane Mitigated β-Amyloid-Induced Neurotoxicity and Acetylcholinesterase Enzyme Activity: In Silico, In Vitro, and Network Pharmacology Study · 2024 · DOI

  • Current treatments for AD may only help temporarily and cannot stop or reverse the disease, - The diagnostic procedure for AD is complex and requires the exclusion of conditions with similar symptoms, - There is no single test for AD, - Earlier treatment options have been limited as they work by targeting…

    Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease · 2024 · DOI

  • Further development and optimization of the synthesized compounds for clinical use. Evaluation of the efficacy and safety of the compounds in animal models and human clinical trials.

    Synthesis and Evaluation of Acetylcholinesterase Inhibitory Activity of Novel 2-Aminobenzothiazole-Based Acetamide Derivatives · 2026 · DOI

  • The evaluation of the in vivo efficacy of the most potent compounds. The investigation of the potential side effects and toxicity of these compounds. The development of novel compounds with improved inhibitory activities and selectivity.

    Synthesis and inhibitory activity of novel N-phenethylpiperidinehydrazide hydrazones against acetylcholinesterase, butyrylcholinesterase, and β-Amyloid (1–42) as potential anti-Alzheimer agents · 2026 · DOI

  • Experimental validation of Cannabicyclol as a potential MAO-B inhibitor. Further studies on the therapeutic potential of cannabis constituents in PD treatment. Investigation of the pharmacological profile of Cannabicyclol.

    Exploring the Therapeutic Potential of Cannabis Constituents in Parkinson's Disease: Insights from Molecular Docking Simulations · 2026 · DOI

Most-cited papers in Cholinesterase and Neurodegenerative Diseases

Most recent work

Find a gap in your own Cholinesterase and Neurodegenerative Diseases sub-topic

This page shows what the Cholinesterase and Neurodegenerative Diseases literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) Future research should focus on designing multitarget chalcone hybrids capable of simultaneously modulating cholinesterases, MAO-B, oxidative stress, inflammation, and amyloid pathways (“Substituted Chalcones as Neuroprotective Agents: A Review”, 2026); (2) There is a need for more effective and selective inhibitors of acetylcholinesterase and butyrylcholinesterase (“Bis -Schiff base derivatives of S -flurbiprofen as potent dual cholinesterase…”, 2026); (3) There is a need for new therapeutic agents for metabolic and neurodegenerative diseases (“Oxidative stress mitigation by leaves of Dodonaea viscosa Jacq. flavonoid-rich…”, 2026); (4) Future studies should investigate the experimental validation of the findings (“In silico investigation of thiazole–semicarbazide hybrids as dual GSK-3β/Tau…”, 2026); (5) The lack of efficacy in reversing okadaic acid-induced toxicity highlights the need for further structural optimization to broaden the neuroprotective spectrum (“Neuroprotective Evaluation of N-Benzyl-2-[4-(Aryl)-1H-1,2,…”, 2026). 178 gap statements have been mined from Cholinesterase and Neurodegenerative Diseases papers in our 7.9M-paper local library, which holds 777 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.